Next step, the Apple iPharm?
This article was originally published in Scrip
Apple Inc, which on 20 July surpassed Microsoft's 1999 mark to become the most valuable publicly quoted corporation in history with a market capitalisation of $623.5 billion, is a business so unlike anything in the pharmaceutical sphere that cross-sectoral lessons can only be learned by contrast.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.